3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
Oxaliplatin
8
Fluorouracil
8
pembrolizumab
7
Paclitaxel
6
Trastuzumab
5
Leucovorin
5
Capecitabine
5
Specimen Handling
4
Radiation
4
Cisplatin
4
Carboplatin
4
tislelizumab
3
patritumab deruxtecan
3
Taxes
3
Radiotherapy
3
Nivolumab
3
ulixertinib
2
trastuzumab deruxtecan
2
trastuzumab biosimilar HLX02
2
durvalumab
2
Surgical Procedures, Operative
2
Ramucirumab
2
Pemetrexed
2
PF-05280014
2
Ontruzant
2
Ogivri
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Immunotherapy
2
Exercise
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Histamine H2 Antagonists
×
30 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled